• 1
    Cutler DM, Everett W. Thinking outside the pillbox – medication adherence as a priority for healthcare reform. N Engl J Med 2010; 362: 15535.
  • 2
    Horne R, Weinman J, Barber N, Elliott R, Morgan M. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO), December 2005.
  • 3
    Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999; 14: 124.
  • 4
    Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398407.
  • 5
    Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008; 65: 65360.
  • 6
    Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008; 64: 112532.
  • 7
    Broussard CS, Louik C, Honein MA, Mitchell AA and the National Birth Defects Prevention Study. Herbal use before and during pregnancy. Am J Obstet Gynecol 2010; 202: 443.
  • 8
    Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S and the National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011; 205: e18.
  • 9
    Crespin S, Bourrel R, Hurault-Delarue C, Lapeyre-Mestre M, Montastruc J-L, Damase-Michel C. Drug prescribing before and during pregnancy in south west France – a retrospective study. Drug Saf 2011; 34: 595604.
  • 10
    Aviv R, Chubb K, Lindow S. The prevalence of maternal medication ingestion in the antenatal period. S Afr Med J 1993; 83: 65760.
  • 11
    Refuuerzo J, Blackwell S, Sokol R, Lajeunesse L, Firchau K, Kruger M, Sorokin Y. Use of over the counter medications and herbal remedies in pregnancy. Am J Perinatol 2005; 22: 3214.
  • 12
    Sawicki E, Stewart K, Wong S, Leung L, Paul E, George J. Medication use for chronic health conditions by pregnant women attending an Australian maternity hospital. Aust N Z J Obstet Gynaecol 2011; 51: 3338.
  • 13
    Sanz E, Gomez-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 2001; 95: 12731.
  • 14
    Nordeng H, Ystrom E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 2010; 66: 20714.
  • 15
    Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26: 448.
  • 16
    Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: Evaluation of perception of risk, efficacy of evidence based counselling and determinants of decision making. Arch Womens Ment Health 2005; 8: 21420.
  • 17
    Vaz MJR, Barros SMO, Palacios R, Senise JF, Lunardi L, Amed AM, Castelo A. HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD AIDS 2007; 18: 2832.
  • 18
    Ickovics JR, Wilson TE, Royce RA, Minkoff HL, Fernandez MI, Fox-Tierney R, Koenig LJ for the Perinatal Guidelines Evaluation Group. Pre-natal and postnatal zidovudine adherence among pregnant women with HIV. J Acquir Immune Defic Syndr 2002; 30: 31115.
  • 19
    Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, Higgins A, Zorrilla C, Landesman S, Serchuck L, LaRussa P. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 2008; 20: 95868.
  • 20
    Smith A, Williams S. Side effect perception and adherence to fertility drugs during IVF treatment. (abstract). Int J Pharm Pract 2010; 18(Suppl. 1): 469.
  • 21
    CMACE. Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–2008. BJOG 2011; 118: 1203.
  • 22
    Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 5959.
  • 23
    Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697706.
  • 24
    Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium – a register-based case–control study. Am J Obstet Gynecol 2008; 198: 233.e17.
  • 25
    Wik HS, Enden TR, Jacobsen AF, Sandset PM. Long-term quality of life after pregnancy-related deep vein thrombosis and the influence of socioeconomic factors and co-morbidity. J Thromb Haemost 2011; 9: 19316.
  • 26
    Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium, Guideline no.37. London: RCOG Press, 2009.
  • 27
    Greer IA, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128: 593601.
  • 28
    Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e691s736s.
  • 29
    Di Matteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 2009.
  • 30
    Clifford S, Barber N, Elliott R, Hartley E, Horne R. Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci 2006; 28: 16570.
  • 31
    Colwell CW, Pulido P, Hardwick ME, Morris BA. Patient compliance with outpatient prophylaxis: an observational study. Orthopaedics 2005; 28: 1437.
  • 32
    Watts AC, Howie CR, Simpson AHRW. Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg 2006; 88-B: 10710.
  • 33
    Bergqvist D, Arcelus JI, Felicissimo P for the ETHOS investigators. Post-discharge compliance to venous thromboembolism prophylaxis in high-risk orthopaedic surgery – results from the ETHOS registry. Thromb Haemost 2012; 107: 2807.
  • 34
    Kingdom JCP, Walker M, Proctor LK, Keating S, Shah PS, Mcleod A, Keunen J, Windrim RC, Dodd JM. Unfractionated heparin for second trimester placental insufficiency: a pilot randomised trial. J Thromb Haemost 2011; 9: 148393.
  • 35
    McLintock C, McCowan LME, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. J Obstet Gynaecol 2009; 116: 158592.
  • 36
    Mengiardi S, Tsakiris DA, Lampert ML, Hersberger KE. Drug use problems with self-injected low-molecular-weight heparins in primary care. Eur J Clin Pharmacol 2011; 67: 10920.
  • 37
    Spahn G. Compliance with self-administration of heparin injections in outpatients. Eur J Trauma 2002; 28: 1049.